Inclusion Criteria:  Aged ≥ 18 years; Diagnosis of clinically moderate to severe plaque-psoriasis; Initiating treatment with secukinumab during the identification period or within 30 days prior to the index date; Patient agrees to sign the informed consent  Exclusion Criteria:  - Participation in any dermatology or rheumatology clinical trial, concurrent or within the last 30 days of the secukinumab initiating date